Eyenovia (NASDAQ:EYEN) Earns “Neutral” Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Eyenovia (NASDAQ:EYEN) in a report published on Thursday,Benzinga reports. The brokerage currently has a $2.00 price objective on the stock. HC Wainwright also issued estimates for Eyenovia’s FY2029 earnings at $1.40 EPS.

EYEN has been the topic of a number of other reports. Brookline Capital Management restated a “hold” rating on shares of Eyenovia in a report on Friday, November 15th. William Blair restated a “market perform” rating on shares of Eyenovia in a research note on Friday, November 15th. Finally, LADENBURG THALM/SH SH reaffirmed a “neutral” rating on shares of Eyenovia in a research report on Monday, November 18th.

Eyenovia Price Performance

Shares of NASDAQ EYEN opened at $2.04 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a 50-day moving average of $6.67 and a 200 day moving average of $33.30. Eyenovia has a 1 year low of $2.01 and a 1 year high of $205.60.

Eyenovia (NASDAQ:EYEN) last released its earnings results on Tuesday, November 12th. The company reported ($8.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($10.40) by $1.60. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period last year, the business posted ($14.40) earnings per share. Research analysts anticipate that Eyenovia will post -0.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Financial Management Network Inc. purchased a new stake in shares of Eyenovia in the third quarter valued at about $39,000. Nations Financial Group Inc. IA ADV boosted its position in shares of Eyenovia by 78.6% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock worth $47,000 after buying an additional 40,000 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Eyenovia by 36.6% in the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock worth $288,000 after acquiring an additional 149,471 shares during the last quarter. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.